Uncategorized
Clearside’s triamcinolone acetonide formulation achieves primary endpoint in phase 2 clinical trial
Clearside Biomedical reported in a press release that its triamcinolone acetonide formulation candidate Zuprata achieved its primary endpoint of reducing the need for Eylea retreatments in patients with macular edema associated with retinal vein occlusion.In the phase 2 masked, controlled Tanzanite trial, participants were randomized to receive either intravitreal Eylea (aflibercept, Regeneron) alone or both intravitreal Eylea and suprachoroidal triamcinolone acetonide at the same time, according to the release.